CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
BeOne Medicines
Merck Sharp & Dohme LLC
Genmab
AbbVie
Genmab
FBD Biologics Limited
Janssen Research & Development, LLC
AbbVie
Actuate Therapeutics Inc.
Pfizer
Acerta Pharma BV
AbbVie
Cellectar Biosciences, Inc.
Janssen Biotech, Inc.
AbbVie
Werewolf Therapeutics, Inc.
AbbVie
AbbVie
AbbVie
Pfizer
Werewolf Therapeutics, Inc.
Eli Lilly and Company
OncoNano Medicine, Inc.
First Ascent Biomedical Inc.
Janssen Research & Development, LLC
AbbVie
Recursion Pharmaceuticals Inc.
AbbVie
Massive Bio, Inc.
AVM Biotechnology Inc
Kyowa Kirin Co., Ltd.
BeiGene
Nurix Therapeutics, Inc.
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Cytosite Biopharma Inc.
ALX Oncology Inc.
Genmab
Biomea Fusion Inc.
Trishula Therapeutics, Inc.
AbbVie
CytomX Therapeutics
Cogent Biosciences, Inc.
Novartis
CARGO Therapeutics
Tempus AI
Celgene
Xynomic Pharmaceuticals, Inc.
Genmab